Fig. 7: Effect of EHF-SF-L285.
From: EHF suppresses cancer progression by inhibiting ETS1-mediated ZEB expression
A ZEB1 promoter activities were determined by luciferase assays (top panel), followed by IB (bottom panel), after cells had been transfected with the indicated plasmids. Each value represents the mean ± s.d. of triplicate determinations from a representative experiment. Similar results were obtained in at least three independent experiments. B, C, D, E, F, and G HSC4 and OTC04 cells were infected with either control (cont.) or flag-tagged EHF-SF-L285P and subjected to IB (B), motility assays (C), chemoresistance assays (D), and proliferation assays (E). HSC4 cells infected with lentiviruses carrying either control (n = 7) or flag-tagged EHF-SF-L285P (n = 8) were injected into the periosteal region of the parietal bone in mice. Five weeks later, mice were sacrificed and specimens were prepared after decalcification. Typical histology in hematoxylin and eosin staining are shown (F), followed by statistical analysis (G). T tumor, B bone, F fibrous tissue. p values were determined by Student’s t-test. *p < 0.01. H Human osteosarcoma 143B-Luc cells infected with either control (n = 5) or EHF-SF-L285P (n = 5) were injected intravenously into the lateral tail vein of mice. After mice were anesthetized with isoflurane on day 14, D-luciferin potassium salt was injected intravenously, followed by measurement of the emission intensity using the IVIS Lumina imaging system (left) and quantification analysis (right).
